Skip to main content

Tarsus Pharmaceuticals, Inc.

TARS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001819790

In the last 90 days, Tarsus Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 256 institutions reported holding it in 13F filings for Q2 2026, worth $2.98B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Tarsus Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
6 filings
4 insiders, $5.19M in total
Insiders trading
4
Net value
−$5.19M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Tarsus Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Tarsus Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Pyott David E IDirector9,575IndirectSep 17, 20264
Yarno Wendy LDirector16,956Sep 17, 20263
Link William J PhDDirector94,487Sep 17, 20266
Azamian Bobak R.President/CEO and Board Chair827,991IndirectSep 9, 20268
Lin Elizabeth YeuChief Medical Officer1,590IndirectSep 9, 20266
Neervannan SeshadriChief Operating Officer78,532Sep 9, 20267
Chaudhuri BhaskarDirector11,654Jun 29, 20262
Morrison Scott WDirector7,638Jun 29, 20262
Goldberg Andrew D.Director19,654Jun 29, 20262
Goodrich KatherineDirector2,233Jun 29, 20264
Farrow Jeffrey SSee Remarks56,801Jun 17, 20264
Mottiwala AzizChief Commercial Officer61,480Mar 19, 20263
Whitfield Dianne C.Chief Human Resources Officer35,028Mar 19, 20265
Wahl BryanGeneral Counsel63,959Mar 19, 20263
Crane Rosemary ADirector5,350Jun 25, 20240
Trevejo Jose M.CHIEF MEDICAL OFFICER2,251Dec 22, 20230
Greenstein Leonard M.Chief Financial Officer26,785Apr 21, 20230
Holdbrook Mark J.V.P., Clinical Affairs3,191Mar 21, 20230
Ackermann MichaelDirector1,208,273Jul 1, 20220
Vivo Capital Fund IX, L.P.10% Owner2,469,001IndirectMay 5, 20220
Vivo Capital IX, LLC10% Owner2,469,001IndirectMay 5, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 17, 2026 (view filing)4:22 PM ETSep 152 daysLink William J PhDDirectorSSale−12.5K$78.38−$979.7K−11.7%94.5K after3 lots10b5-1
Sep 9, 2026 (view filing)4:14 PM ETSep 45 daysAzamian Bobak R.President/CEO and Board ChairSSale−10.0K$90.56−$905.6K−1.2%828.0K after2 lots10b5-1
Sep 9, 2026 (view filing)4:13 PM ETSep 45 daysLin Elizabeth YeuChief Medical OfficerSSale−10.8K$87.50−$942.6K−80.9%2.55K after2 lots10b5-1
Sep 9, 2026 (view filing)4:13 PM ETSep 45 daysLin Elizabeth YeuChief Medical OfficerSSale−3.18K$87.50−$278.3K−66.7%1.59K after2 lots10b5-1
Sep 9, 2026 (view filing)4:12 PM ETSep 45 daysNeervannan SeshadriChief Operating OfficerSSale−4.56K$85.00−$387.9K−5.5%78.5K after10b5-1
Sep 3, 2026 (view filing)4:30 PM ETSep 21 dayAzamian Bobak R.President/CEO and Board ChairSSale−10.0K$80.06−$800.6K−1.2%838.0K after10b5-1
Sep 3, 2026 (view filing)4:29 PM ETSep 1-22 daysLin Elizabeth YeuChief Medical OfficerSSale−9.99K$77.17−$770.8K−42.9%13.3K after2 lots10b5-1
Sep 3, 2026 (view filing)4:29 PM ETSep 21 dayLin Elizabeth YeuChief Medical OfficerSSale−1.59K$80.00−$127.2K−25.0%4.77K after10b5-1
Jun 22, 2026 (view filing)Jun 175 daysAzamian Bobak R.President/CEO and Board ChairSSale−10.0K$61.55−$615.5K−1.2%848.0K after2 lots10b5-1
Jun 17, 2026 (view filing)Jun 152 daysGoodrich KatherineDirectorSSale−2.95K$62.08−$183.4K−57.0%2.23K after10b5-1
Jun 17, 2026 (view filing)Jun 161 dayFarrow Jeffrey SSee RemarksSSale−14.4K$60.95−$877.4K−20.2%56.8K after
Jun 17, 2026 (view filing)Jun 152 daysLink William J PhDDirectorSSale−12.5K$62.12−$776.5K−10.5%106.8K after2 lots10b5-1
Mar 24, 2026 (view filing)Mar 204 daysNeervannan SeshadriChief Operating OfficerSSale−2.99K$66.75−$199.5K−3.5%82.8K after10b5-1
Mar 19, 2026 (view filing)Mar 17-192 daysLin Elizabeth YeuChief Medical OfficerSSale−1.14K$68.36−$78.2K−4.7%23.3K after3 lots
Mar 19, 2026 (view filing)Mar 17-192 daysWahl BryanGeneral CounselSSale−12.4K$68.36−$850.4K−16.3%64.0K after3 lots
Mar 19, 2026 (view filing)Mar 17-192 daysWhitfield Dianne C.Chief Human Resources OfficerSSale−12.3K$68.36−$839.1K−25.9%35.0K after3 lots
Mar 19, 2026 (view filing)Mar 17-192 daysAzamian Bobak R.President/CEO and Board ChairSSale−34.6K$68.34−$2.36M−50.9%33.4K after3 lots
Mar 19, 2026 (view filing)Mar 17-192 daysNeervannan SeshadriChief Operating OfficerSSale−11.3K$68.21−$772.4K−11.7%85.8K after3 lots
Mar 19, 2026 (view filing)Mar 17-192 daysMottiwala AzizChief Commercial OfficerSSale−13.1K$68.36−$892.5K−17.5%61.5K after3 lots
Mar 19, 2026 (view filing)Mar 17-192 daysFarrow Jeffrey SSee RemarksSSale−6.43K$68.36−$439.6K−12.9%43.3K after3 lots
Mar 18, 2026 (view filing)Mar 162 daysLink William J PhDDirectorSSale−12.5K$68.79−$859.8K−9.7%116.3K after3 lots10b5-1
Mar 5, 2026 (view filing)Mar 41 dayNeervannan SeshadriChief Operating OfficerSSale−8.37K$76.67−$641.4K−10.6%70.8K after10b5-1
Jan 6, 2026 (view filing)Jan 24 daysWhitfield Dianne C.Chief Human Resources OfficerSSale−15.6K$80.67−$1.26M−40.0%23.4K after4 lots10b5-1
Dec 30, 2025 (view filing)Dec 246 daysAzamian Bobak R.President/CEO and Board ChairSSale−6.00K$82.51−$495.1K−0.7%858.0K after2 lots10b5-1
Dec 18, 2025 (view filing)Dec 162 daysWhitfield Dianne C.Chief Human Resources OfficerSSale−7.40K$80.10−$592.5K−16.0%39.0K after10b5-1
Dec 17, 2025 (view filing)Dec 161 dayLin Elizabeth YeuChief Medical OfficerSSale−2.08K$79.50−$165.2K−8.7%21.9K after
Dec 17, 2025 (view filing)Dec 152 daysLink William J PhDDirectorSSale−12.5K$81.43−$1.02M−8.8%128.8K after3 lots10b5-1
Dec 17, 2025 (view filing)Dec 152 daysLink William J PhDDirectorSSale−10.4K$81.07−$846.9K−100.0%0 after2 lots10b5-1
Sep 26, 2025 (view filing)Sep 242 daysAzamian Bobak R.President/CEO and Board ChairSSale−6.00K$55.37−$332.2K−0.7%812.1K after10b5-1
Sep 10, 2025 (view filing)Sep 82 daysLink William J PhDDirectorSSale−27.1K$57.00−$1.55M−15.9%143.3K after
Aug 13, 2025 (view filing)Aug 112 daysAzamian Bobak R.President/CEO and Board ChairSSale−6.00K$50.00−$300.0K−0.7%818.1K after10b5-1
Jun 18, 2025 (view filing)Jun 171 dayFarrow Jeffrey SSee RemarksSSale−13.6K$40.42−$550.0K−27.0%36.7K after
Jun 17, 2025 (view filing)Jun 161 dayLin Elizabeth YeuChief Medical OfficerSSale−1.01K$41.08−$41.3K−11.6%7.69K after
Jun 11, 2025 (view filing)Jun 92 daysMottiwala AzizChief Commercial OfficerSSale−17.5K$43.76−$765.8K−26.9%47.6K after10b5-1
Mar 26, 2025 (view filing)Mar 242 daysAzamian Bobak R.President/CEO and Board ChairSSale−6.00K$50.00−$300.0K−0.7%824.1K after
Mar 20, 2025 (view filing)Mar 18-202 daysMottiwala AzizChief Commercial OfficerSSale−10.6K$47.88−$505.9K−14.0%65.1K after3 lots
Mar 20, 2025 (view filing)Mar 18-202 daysNeervannan SeshadriChief Operating OfficerSSale−7.58K$47.89−$363.1K−8.7%79.7K after3 lots
Mar 20, 2025 (view filing)Mar 18-202 daysWahl BryanGeneral CounselSSale−9.69K$47.88−$463.8K−15.8%51.7K after3 lots
Mar 20, 2025 (view filing)Mar 18-202 daysWhitfield Dianne C.Chief Human Resources OfficerSSale−6.71K$47.88−$321.3K−12.6%46.4K after3 lots
Mar 20, 2025 (view filing)Mar 18-202 daysAzamian Bobak R.President/CEO and Board ChairSSale−24.2K$48.03−$1.16M−31.1%53.6K after3 lots
Mar 20, 2025 (view filing)Mar 18-202 daysFarrow Jeffrey SSee RemarksSSale−3.72K$47.88−$178.3K−14.2%22.4K after3 lots
Aug 14, 2024 (view filing)Aug 122 daysLink William J PhDDirectorSSale−35.0K$26.08−$913.0K−100.0%0 after2 lots
Jun 20, 2024 (view filing)Jun 182 daysFarrow Jeffrey SSee RemarksSSale−10.4K$27.47−$286.9K−36.5%18.1K after
Mar 19, 2024 (view filing)Mar 181 dayMottiwala AzizChief Commercial OfficerSSale−4.77K$30.60−$145.8K−8.1%54.1K after
Mar 19, 2024 (view filing)Mar 181 dayWahl BryanGeneral CounselSSale−4.44K$30.60−$135.7K−9.8%41.0K after
Mar 19, 2024 (view filing)Mar 181 dayAzamian Bobak R.President/CEO and Board ChairSSale−10.4K$30.60−$318.7K−28.2%26.5K after
Mar 19, 2024 (view filing)Mar 181 dayWhitfield Dianne C.Chief Human Resources OfficerSSale−4.31K$30.60−$132.0K−11.2%34.2K after
Mar 19, 2024 (view filing)Mar 181 dayNeervannan SeshadriChief Operating OfficerSSale−4.88K$30.60−$149.3K−7.0%64.8K after
Dec 29, 2023 (view filing)Dec 272 daysAzamian Bobak R.President/CEO and Board ChairSSale−8.00K$20.22−$161.8K−1.0%830.1K after10b5-1
Dec 22, 2023 (view filing)Dec 202 daysAzamian Bobak R.President/CEO and Board ChairSSale−40.0K$20.27−$810.6K−4.6%838.1K after2 lots10b5-1